Amid rising concerns over antibiotic resistance, the U.S. Department of Health and Human Services is moving to encourage Congress to create a novel incentive program for drug companies to develop these life-saving medicines.
In a document issued by the G7 Finance Ministers earlier this week, the U.S. Treasury Department disclosed the Biden administration supports existing legislation, known as the Pasteur Act, which would establish a payment mechanism for drug developers. But if the bill fails to become law, HHS is taking steps required to submit a similar proposal to Congress in order to accomplish the same goal.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
